- Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
- Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences
- Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020
- Eiger to Present at Jefferies Virtual Healthcare Conference 2020
- Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies
Eiger BioPharmaceuticals Inc (72C1:FRA) closed at 9.60, -31.43% below its 52-week high of 14.00, set on Dec 27, 2019.
4.32Mar 16 202014.00Dec 27 2019
Markit short selling activity
|Market cap||330.15m USD|
|EPS (TTM)||-2.68 |
Data delayed at least 15 minutes, as of Aug 14 2020 07:07 BST.